A New Therapeutic Approach Using a Schizophyllan-based Drug Delivery System for Inflammatory Bowel Disease
Hidetoshi Takedatsu(Kurume University), Michio Sata(Kurume University), Keiichi Mitsuyama(Kurume University), Teppei Kobayashi(Kurume University), Shinichi Mochizuki(The University of Kitakyushu), Kazuo Sakurai(The University of Kitakyushu), Jun Nishihira(Hokkaido Information University), Yoshihide Fujiyama(Shiga University of Medical Science), Hiroshi Takeda(Hokkaido University), Yoshikazu Koyama(Howard Hughes Medical Institute)
Cited by 70
Related Papers
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536
Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice
|Clinical Immunology|2003|491